Latest in Lilly Mojo
Sort by
84 items
-
Eli Lilly has its mojo back ahead of a pivotal year for the obesity drug giant
The drugmaker is not perfect, as the past few months showed, but it's still a thoroughbred.CNBC - 11h -
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short
Zepbound and Mounjaro have now underperformed expectations for two straight quarters.CNBC - 13h -
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.CNBC - 13h -
Lilly’s Mounjaro and Zepbound contribute to big revenue boost, drugmaker says
Eli Lilly has “tremendous momentum” entering 2025, CEO David A. Ricks said Thursday.MarketWatch - 14h -
Brown takes on Princeton following Lilly's 34-point game
Brown plays the Princeton Tigers after Kino Lilly Jr. scored 34 points in the Bears' 88-79 win against the Pennsylvania QuakersABC News - 5d -
Lilly scores 34, Brown beats Pennsylvania 88-79
The Brown Bears defeated the Pennsylvania Quakers 88-79 on Friday night led by Kino Lilly Jr.'s 34 pointsABC News - 6d -
Jim Cramer's week ahead: Earnings from Amazon, Alphabet, Eli Lilly, Palantir
CNBC's Jim Cramer on Friday walked investors through an earnings-heavy week.CNBC - 6d -
Is a Celtics rotation tweak helping starters regain their mojo?
Has Joe Mazzulla found the secret to unlocking the Celtics' starting five? Chris Forsberg explores the impact of a recent rotation shift in Boston.Yahoo Sports - Jan. 21 -
Eli Lilly CEO expects new weight loss pill to be approved next year
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.CNBC - Jan. 13 -
Eli Lilly strikes deal for cancer treatment, gives timeline for weight loss pill
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.CNBC - Jan. 13 -
Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency says
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other insurance plans for weight loss.CNBC - Jan. 9 -
Medicare can cover Zepbound for sleep apnea, creating a significant opportunity for Eli Lilly
Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment costs about $1,000 a month without insurance.MarketWatch - Jan. 9 -
Eli Lilly's lead in the obesity race has grown. Its recent stock performance says otherwise
Eli Lilly has been one of the worst-performing Club stocks over the past six months.CNBC - Jan. 8
